Quantcast

Latest HCV Stories

2014-05-21 12:49:39

American Chemical Society To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way. Now scientists are solving another side of the disease's problem: identifying the millions more who have the virus but don't know it — and unwittingly pass it on. A report in the ACS journal Analytical Chemistry describes a novel, scrapbook-inspired test that does just that. Xuan Mu, Zhi Zheng...

2014-05-20 04:21:04

GENEVA, May 20, 2014 /PRNewswire/ -- The International Federation of Pharmaceutical Manufacturers and Associations [http://www.ifpma.org ] (IFPMA) has published today a new report and recommendations on Hepatitis, encouraging a comprehensive approach to fighting this silent epidemic. Titled "Towards a Sustainable, Intersectoral Approach to Viral Hepatitis [http://www.ifpma.org/fileadmin/content/Publication/2014/IFPMA_Viral_Hepatitis_May2014.pdf ] ", the report is meant to...

2014-05-19 10:12:50

University at Buffalo More effective, new medications for HCV infection with fewer side effects also are causing a shift in patients’ attitudes People who inject drugs and are enrolled in a drug treatment program are receptive to education about, and treatment for, hepatitis C virus, according to a study by researchers at several institutions, including the University at Buffalo. That finding, published online this week in the Journal of Addiction Medicine will be welcome news to...

2014-05-12 08:30:57

MILFORD, Mass., May 12, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the...

2014-05-05 10:33:42

Consumption of alcohol has long been associated with an increased risk of advanced liver fibrosis, but a new study published online in Clinical Infectious Diseases from researchers at Penn Medicine and other institutions shows that association is drastically heightened in people co-infected with both HIV and chronic hepatitis C virus (HCV) infection. Even light ("nonhazardous") drinking—which typically poses a relatively low risk for uninfected persons—was linked to an increased risk of...

2014-05-02 12:26:36

New research finds Vietnam vets with hepatitis C do not have higher rates of the disease DANVILLE, Pa., May 2, 2014 /PRNewswire-USNewswire/ -- A team of researchers from four health systems across the United States has published a study revealing that Vietnam era vets with hepatitis C virus (HCV) do not have higher rates of this disease due to injection drug abuse compared to nonveterans. The study was published electronically in the Journal of Community Health in April. It is...

2014-04-22 08:34:00

-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by...

2014-04-14 12:51:21

The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase...

2014-04-14 12:35:09

Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients. Overall, 65.4% of patients...

2014-04-14 12:33:05

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular...


Latest HCV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.